• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在缺乏特定疾病数据的情况下,使用来自一般人群的健康状态效用值来近似决策分析模型中的基线。

Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available.

机构信息

The University of Sheffield, Sheffield, UK.

出版信息

Value Health. 2011 Jun;14(4):539-45. doi: 10.1016/j.jval.2010.10.029. Epub 2011 Apr 22.

DOI:10.1016/j.jval.2010.10.029
PMID:21669378
Abstract

BACKGROUND

Decision analytic models in health care require baseline health-related quality of life data to accurately assess the benefits of interventions. The use of inappropriate baselines such as assuming the value of perfect health (EQ-5D = 1) for not having a condition may overestimate the benefits of some treatment and thus distort policy decisions informed by cost per quality adjusted life years thresholds.

OBJECTIVE

The primary objective was to determine if data from the general population are appropriate for baseline health state utility values (HSUVs) when condition specific data are not available.

METHODS

Data from four consecutive Health Surveys for England were pooled. Self-reported health status and EQ-5D data were extracted and used to generate mean HSUVs for cohorts with or without prevalent health conditions. These were compared with mean HSUVs from all respondents irrespective of health status.

RESULTS

More than 45% of respondents (n = 41,174) reported at least one condition and almost 20% reported at least two. Our results suggest that data from the general population could be used to approximate baseline HSUVs in some analyses, but not all. In particular, HSUVs from the general population would not be an appropriate baseline for cohorts who have just one condition. In these instances, if condition specific data are not available, data from respondents who report they do not have any prevalent health condition may be more appropriate. Exploratory analyses suggest the decrement on health-related quality of life may not be constant across ages for all conditions and these relationships may be condition specific. Additional research is required to validate our findings.

摘要

背景

医疗保健中的决策分析模型需要基线健康相关生活质量数据,以准确评估干预措施的益处。使用不适当的基线,例如假设不存在疾病的完美健康状态(EQ-5D=1),可能会高估某些治疗方法的益处,从而扭曲基于成本效益阈值的政策决策。

目的

主要目的是确定在没有特定疾病数据的情况下,来自一般人群的数据是否适合作为基线健康状态效用值(HSUV)。

方法

汇集了英格兰连续四次健康调查的数据。提取自我报告的健康状况和 EQ-5D 数据,并用于为有或没有现有健康状况的队列生成平均 HSUV。将这些数据与不论健康状况如何的所有受访者的平均 HSUV 进行比较。

结果

超过 45%的受访者(n=41174)报告了至少一种疾病,近 20%的受访者报告了至少两种疾病。我们的研究结果表明,在某些分析中,可以使用一般人群的数据来近似基线 HSUV,但并非所有情况都适用。特别是,对于只有一种疾病的队列,一般人群的 HSUV 不是合适的基线。在这些情况下,如果没有特定疾病的数据,那么报告没有任何现有健康状况的受访者的数据可能更合适。探索性分析表明,所有疾病的健康相关生活质量的下降并非在所有年龄段都保持不变,并且这些关系可能是特定于疾病的。需要进一步的研究来验证我们的发现。

相似文献

1
Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available.在缺乏特定疾病数据的情况下,使用来自一般人群的健康状态效用值来近似决策分析模型中的基线。
Value Health. 2011 Jun;14(4):539-45. doi: 10.1016/j.jval.2010.10.029. Epub 2011 Apr 22.
2
Populating an economic model with health state utility values: moving toward better practice.用健康状态效用值填充经济模型:迈向更好的实践。
Value Health. 2010 Aug;13(5):509-18. doi: 10.1111/j.1524-4733.2010.00700.x. Epub 2010 Mar 10.
3
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.质量调整生命年在儿科护理中缺乏质量:对已发表的儿童健康成本效用研究的批判性综述。
Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127.
4
A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.一项针对精神分裂症患者的研究中SF-6D与EQ-5D效用评分的比较。
J Ment Health Policy Econ. 2009 Mar;12(1):27-31.
5
Estimating EuroQol EQ-5D scores from Population Healthy Days data.根据人群健康天数数据估算欧洲五维度健康量表(EuroQol EQ-5D)得分。
Med Decis Making. 2008 Jul-Aug;28(4):491-9. doi: 10.1177/0272989X07312708. Epub 2008 Jun 12.
6
Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.评估类风湿关节炎中的效用值:时间权衡法与欧洲五维度健康量表的比较
Arthritis Rheum. 2006 Oct 15;55(5):751-6. doi: 10.1002/art.22226.
7
Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire.牛津郡季节性过敏性结膜炎的经济影响及生活质量影响
Ophthalmic Epidemiol. 2004 Feb;11(1):17-33. doi: 10.1076/opep.11.1.17.26437.
8
Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.使用哪种与健康相关的生活质量评分?ADVANCE试验中2型糖尿病患者替代效用测量方法的比较。
Health Qual Life Outcomes. 2007 Apr 27;5:21. doi: 10.1186/1477-7525-5-21.
9
The validity of EQ-5D US preference weights in liver transplant candidates and recipients.EQ-5D美国偏好权重在肝移植候选者和接受者中的有效性。
Liver Transpl. 2009 Jan;15(1):88-95. doi: 10.1002/lt.21648.
10
Alcohol consumption, abstaining, health utility, and quality of life--a general population survey in Finland.饮酒、戒酒、健康效用与生活质量——芬兰一项普通人群调查
Alcohol Alcohol. 2008 May-Jun;43(3):376-86. doi: 10.1093/alcalc/agn003. Epub 2008 Feb 1.

引用本文的文献

1
Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares.使用传播模型对日本流感治疗进行成本效益分析:巴洛沙韦和奥司他韦份额的影响
Infect Dis Ther. 2025 Aug 27. doi: 10.1007/s40121-025-01203-5.
2
Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China.在中国,布加替尼与阿来替尼用于一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学分析
Oncol Ther. 2025 Jul 24. doi: 10.1007/s40487-025-00361-3.
3
Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment.
意大利婴儿中使用呼吸道合胞病毒前体融合蛋白(RSVpreF)疫苗和单克隆抗体进行母体免疫预防呼吸道合胞病毒的补充策略:成本效益评估
Infect Dis Ther. 2025 Jul 18. doi: 10.1007/s40121-025-01193-4.
4
[Not Available].[无可用内容]
Glob Reg Health Technol Assess. 2025 Jul 17;12:168-176. doi: 10.33393/grhta.2025.3403. eCollection 2025 Jan-Dec.
5
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England.一次性上腹部CT筛查作为英国肺癌筛查附加检查的成本效益分析。
Br J Cancer. 2025 May 14. doi: 10.1038/s41416-025-03043-z.
6
A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer.阿贝西利联合辅助内分泌治疗HR+、HER2-、淋巴结阳性、高危早期乳腺癌的成本效益分析
Adv Ther. 2025 Jun;42(6):2767-2781. doi: 10.1007/s12325-025-03164-0. Epub 2025 Apr 8.
7
Normative values for the hypoparathyroidism patient questionnaire (HPQ28) in the German general population.德国普通人群中甲状旁腺功能减退患者问卷(HPQ28)的标准值。
J Patient Rep Outcomes. 2025 Apr 3;9(1):38. doi: 10.1186/s41687-025-00868-3.
8
Quality of life in patients with HBV infection: A systematic review and meta-analysis.乙肝病毒感染患者的生活质量:一项系统评价与荟萃分析。
JHEP Rep. 2025 Jan 8;7(4):101312. doi: 10.1016/j.jhepr.2024.101312. eCollection 2025 Apr.
9
The Cost-Effectiveness of Sentinel Lymph Node Mapping in High-Risk Endometrial Cancer.前哨淋巴结定位在高危子宫内膜癌中的成本效益分析
Cancers (Basel). 2024 Dec 19;16(24):4240. doi: 10.3390/cancers16244240.
10
Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.英格兰高危人群膀胱癌和肾癌的家庭尿液试纸筛查:长期影响和成本效益的微观模拟研究
Pharmacoeconomics. 2025 Apr;43(4):441-452. doi: 10.1007/s40273-024-01463-y. Epub 2025 Jan 3.